Elevance Health, Inc.
ELV
$399.64
+1.61%
Elevance Health, Inc. is a leading health insurer in the United States, providing medical benefits to approximately 45 million members through employer, individual, and government-sponsored plans. The company's distinct competitive identity stems from its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as a licensee in 14 states, and its expanding footprint in government programs and healthcare services through strategic acquisitions. The current investor narrative is heavily influenced by regulatory developments affecting Medicare Advantage payments, as evidenced by recent sector-wide stock movements following a favorable 2027 payment update from CMS, alongside ongoing debates about the company's ability to navigate medical cost trends and execute its integrated health services strategy.…
ELV
Elevance Health, Inc.
$399.64
Investment Opinion: Should I buy ELV Today?
Rating & Thesis: Hold. ELV presents a compelling but high-risk value proposition following a sharp rally; investors should wait for confirmation of earnings stabilization before committing new capital. While institutional analyst sentiment (e.g., Mizuho, JP Morgan) remains bullish, the limited coverage and extreme quarterly volatility warrant caution.
Supporting Evidence: The stock trades at a discounted 12.75x forward P/E, well below historical highs and sector peers, suggesting undervaluation if earnings recover. The 24.85% monthly surge and breakout from a downtrend are technically positive. The company's financial health is strong, with $3.17B in TTM FCF and a manageable 0.76 debt-to-equity ratio. The recent favorable CMS update for 2027 provides a tangible catalyst for the government business segment.
Risks & Conditions: The thesis is invalidated if Q1 2026 margins show further compression from Q4 2025 levels, or if revenue growth decelerates below 5% YoY. This Hold would upgrade to a Buy if the forward P/E remains below 14x while quarterly net margin demonstrates a clear recovery above 3%. It would downgrade to Sell if the stock fails to hold above the $340 support level and trends toward its 52-week low. Currently, the stock appears fairly valued relative to its near-term risk/reward profile, balancing deep value against unproven earnings stability.
Sign up to view all
ELV 12-Month Price Forecast
ELV is at a crossroads. The bullish valuation and regulatory catalyst are compelling, but they are counterbalanced by profound earnings instability and long-term underperformance. The neutral stance reflects the high probability (50%) of a base case where the stock churns within a range as these opposing forces battle. Confidence is medium due to the limited analyst coverage, which reduces visibility. The stance would upgrade to bullish on evidence of two consecutive quarters of margin stabilization or expansion. It would downgrade to bearish if the stock breaks below the $340 support level, signaling the failure of the recent recovery attempt.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Elevance Health, Inc.'s 12-month outlook, with a consensus price target around $519.53 and implied upside of +30.0% versus the current price.
Average Target
$519.53
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$320 - $520
Analyst target range
Analyst coverage for Elevance Health appears limited in the provided dataset, with only 3 analysts cited for estimates, which is insufficient to form a robust consensus view for a company of this size and typically indicates either data gaps or that it is a less-followed name among the major bulge-bracket firms. The provided data shows an average estimated EPS of $46.51 for an unspecified period, but without a consensus price target or clear Buy/Hold/Sell distribution, the signal strength is weak; the recent institutional ratings from firms like Mizuho, JP Morgan, and Barclays all maintain bullish 'Outperform' or 'Overweight' stances, suggesting professional sentiment remains positive. The implications of limited visible coverage include potentially higher volatility and less efficient price discovery, as the stock may be more influenced by direct institutional flows and sector news, such as the recent positive Medicare Advantage update, rather than a broad analyst-driven narrative.
Bulls vs Bears: ELV Investment Factors
The bull case, centered on deep valuation, a powerful technical rebound, and a favorable regulatory shift, currently holds stronger evidence following the 25% monthly surge. However, the bear case, grounded in severe earnings volatility and long-term underperformance, presents a formidable counter-argument. The single most important tension in the investment debate is whether the recent CMS-driven rally marks a sustainable inflection point for margins and earnings stability, or merely a temporary relief rally before the resumption of profit pressure. The resolution of Q1 2026 earnings, specifically the trajectory of net and gross margins, will be the critical determinant of which narrative prevails.
Bullish
- Deep Valuation Discount: Elevance trades at a forward P/E of 12.75x, a significant discount to its historical highs above 35x and below typical managed care peer averages in the mid-teens. This compression implies the market has priced in significant pessimism, offering a substantial margin of safety if fundamentals stabilize.
- Strong Relief Rally & Technical Rebound: The stock has surged 24.85% over the past month, decisively breaking a downtrend and trading at 41% of its 52-week range. This powerful momentum, coupled with a low beta of 0.50, suggests the move is driven by stock-specific positive catalysts, like the favorable CMS payment update, rather than general market strength.
- Robust Balance Sheet & Cash Flow: The company maintains a healthy debt-to-equity ratio of 0.76 and generated $3.17 billion in TTM free cash flow. This strong financial foundation supports shareholder returns and strategic investments, providing stability amid earnings volatility.
- Favorable Regulatory Catalyst: Recent news confirms a larger-than-expected 2027 Medicare Advantage payment increase from CMS. This directly boosts revenue visibility for Elevance's significant government-sponsored business segment, alleviating a key overhang that had pressured the stock.
Bearish
- Severe Earnings & Margin Volatility: Q4 2025 net income collapsed to $547 million (1.10% margin) from $2.18 billion (4.47% margin) in Q1 2025, while gross margin compressed from 27.77% to 23.48%. This extreme quarterly volatility indicates significant underlying pressure from medical cost trends and operational challenges.
- Persistent Year-Over-Year Underperformance: Despite the recent rally, ELV is down 8.73% over the past year, significantly underperforming the SPY's 29.04% gain by nearly 38 percentage points. This long-term relative weakness suggests deep-seated investor concerns that may not be fully resolved by a short-term bounce.
- Limited Analyst Coverage & Visibility: Only 3 analysts are cited for estimates, indicating weak consensus formation and potentially inefficient price discovery. This lack of coverage can lead to higher volatility and makes the stock more susceptible to abrupt sentiment shifts based on sector news flows.
- Revenue Growth Deceleration: While Q4 2025 revenue grew 9.47% YoY, it declined sequentially from Q3's peak of $50.71 billion to $49.75 billion. This suggests growth may be plateauing or facing seasonal headwinds, raising questions about the sustainability of top-line expansion.
ELV Technical Analysis
The stock is in a volatile recovery phase, having experienced a significant drawdown earlier in the year. The 1-year price change is -8.73%, indicating a downtrend over that longer period, but the stock is currently trading at approximately 41% of its 52-week range (current price $372.68 vs. 52-week high $424.24 and low $273.71), suggesting it remains closer to the lower bound and may represent a value opportunity after a sharp decline. Recent momentum, however, has been exceptionally strong, with a 1-month price surge of 24.85% and a 3-month gain of 7.79%, sharply diverging from the negative 1-year trend and signaling a powerful short-term reversal or relief rally. The stock's beta of 0.50 indicates it is approximately 50% less volatile than the broader market (SPY), which is notable given the recent price swings and suggests its moves are driven by idiosyncratic factors rather than market-wide sentiment. Key technical levels are clearly defined, with immediate resistance near the 52-week high of $424.24 and support at the recent low of $273.71; a sustained breakout above resistance would confirm a new bullish trend, while a failure and breakdown below $273.71 would signal a resumption of the prior downtrend.
Beta
0.67
0.67x market volatility
Max Drawdown
-37.7%
Largest decline past year
52-Week Range
$274-$413
Price range past year
Annual Return
+6.5%
Cumulative gain past year
| Period | ELV Return | S&P 500 |
|---|---|---|
| 1m | +26.4% | +8.2% |
| 3m | +18.9% | +9.0% |
| 6m | +22.7% | +10.5% |
| 1y | +6.5% | +26.5% |
| ytd | +12.8% | +8.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ELV Fundamental Analysis
Revenue growth has been solid but decelerating sequentially, with Q4 2025 revenue of $49.75 billion representing a 9.47% year-over-year increase; however, examining the quarterly trend from Q1 to Q4 2025 shows revenue peaked in Q3 at $50.71 billion before dipping slightly, indicating potential stabilization or seasonal patterns. Profitability metrics show significant quarterly volatility, with Q4 2025 net income at $547 million (net margin of 1.10%) and gross margin at 23.48%, a notable compression from the Q1 2025 net income of $2.18 billion (net margin 4.47%) and gross margin of 27.77%, highlighting margin pressure likely from medical cost trends. The balance sheet and cash flow position remains healthy, with a debt-to-equity ratio of 0.76 indicating moderate leverage, a current ratio of 1.24 demonstrating sufficient short-term liquidity, and trailing twelve-month free cash flow of $3.17 billion providing ample internal funding capacity for dividends, buybacks, and investments; the return on equity of 12.90% further underscores efficient capital allocation by management.
Quarterly Revenue
$49.7B
2025-12
Revenue YoY Growth
+0.09%
YoY Comparison
Gross Margin
+0.23%
Latest Quarter
Free Cash Flow
$3.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ELV Overvalued?
Given the company's consistent profitability, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE ratio stands at 13.73x, while the forward PE is slightly lower at 12.75x, indicating the market anticipates modest earnings growth. Compared to sector averages, Elevance trades at a discount; for instance, its forward PE of 12.75x is below the typical managed care peer average often in the mid-teens, suggesting the market may be pricing in concerns over margin compression or regulatory headwinds not fully reflected in the broader industry. Historically, the stock's own valuation has contracted significantly; the current trailing PE of 13.73x is near the bottom of its multi-year range, well below historical highs above 35x seen in late 2025, which implies the stock is pricing in pessimistic expectations and could offer value if fundamentals stabilize or improve.
PE
13.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 11x~50x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary risk is extreme earnings volatility, as evidenced by Q4 2025 net income plummeting 75% from Q1 levels and net margin compressing from 4.47% to 1.10%. This indicates significant sensitivity to medical cost trends and potential mispricing of insurance premiums. While the balance sheet is solid with a 0.76 debt-to-equity ratio, such profit swings undermine valuation stability and investor confidence. Revenue concentration in government-sponsored plans, though a recent tailwind, also exposes the company to future regulatory payment adjustments.
Market & Competitive Risks: Despite its discounted 12.75x forward P/E, the stock faces valuation compression risk if earnings fail to stabilize, potentially driving multiples even lower. The managed care sector is highly competitive and regulated, with margins constantly under scrutiny. The stock's low 0.50 beta suggests it trades on idiosyncratic news, but this also means it can decouple from broader market rallies, as seen in its 38-percentage-point underperformance vs. the SPY over the past year. The high short interest (ratio 2.83) reflects ongoing skepticism that could fuel renewed selling pressure.
Worst-Case Scenario: The worst-case scenario involves a recurrence of severe medical cost inflation coinciding with an unfavorable regulatory update, leading to another significant earnings miss. This could trigger analyst downgrades, a loss of investor confidence, and a retest of the 52-week low of $273.71. From the current price of $372.68, this represents a realistic downside of approximately -27%. A breach of that support could see the stock fall toward the $250 level, aligning with the maximum drawdown of -39.33% experienced earlier in the year.
FAQ
The key risks are, in order of severity: 1) Earnings Volatility Risk: Profits are highly unstable, as seen in the plunge from a 4.47% net margin in Q1 2025 to 1.10% in Q4 2025. 2) Regulatory & Reimbursement Risk: Despite a recent positive update, future changes to Medicare/Medicaid payment rates directly impact a large portion of revenue. 3) Medical Cost Trend Risk: Unpredictable increases in healthcare utilization and costs can rapidly erode margins. 4) Sentiment & Coverage Risk: With only 3 visible analysts, the stock suffers from low visibility and can be prone to sharp sentiment swings, exacerbated by a high short ratio of 2.83.
The 12-month forecast presents three scenarios. The Base Case (50% probability) sees the stock trading between $370 and $410 as earnings volatility moderates but significant multiple expansion is limited. The Bull Case (30% probability), driven by sustained margin recovery, targets $424 to $460. The Bear Case (20% probability), triggered by further profit deterioration, sees a retest of support between $274 and $320. The base case is most likely, anchored by the assumption that the recent positive regulatory catalyst prevents a collapse but does not fully resolve underlying cost pressures in the near term.
ELV stock is statistically undervalued based on its multiples. Its forward P/E of 12.75x is below typical managed care peers and a deep discount to its own historical highs above 35x. The price-to-sales ratio of 0.39 also suggests a low price for each dollar of revenue. However, this discount reflects the market's justified concerns over extreme earnings volatility and margin pressure. The valuation implies the market expects subpar profitability to continue. If the company demonstrates even modest earnings stability, the current price could prove to be a significant bargain.
ELV is a speculative buy for investors with a higher risk tolerance and a value-oriented mindset. At a forward P/E of 12.75x, it appears undervalued relative to its sector and history, offering a 30% probability of rallying to $424+ if earnings stabilize. However, the severe quarterly profit volatility (Q4 net income down 75% from Q1) and 27% potential downside to the 52-week low make it a high-risk proposition. It is a good buy only for those who can stomach volatility and are willing to wait for concrete evidence of margin recovery, likely over a 12-18 month horizon.
ELV is unsuitable for short-term trading due to its low beta (0.50) and idiosyncratic news-driven moves, which make timing difficult. It is best approached as a long-term (3+ year) value investment, allowing time for its integrated health strategy to mature and for management to demonstrate an ability to manage medical cost volatility. The healthy dividend yield (~2%) and strong free cash flow support a long-term holding period. Investors should be prepared for significant volatility along the way and consider a minimum holding period of 18-24 months to allow the investment thesis to play out.